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Abstract: 
Drug cardiotoxicity is one of the main reasons of fatal drug related problem events and the subsequent withdrawals. Therefore, its early assessment is a crucial 
element of the drug development process. For the drug driven hERG inhibition assessment, which is assumed to be the main reason for toxicity, in vitro techniques 
are used. Gold standards are based on the Patch Clamp method with the use of various cell models but due to its low throughput, insilico models have become 
more appreciated. To develop a reliable empirical QSAR model, wide dataset containing a variety of cases has to be available. In this article, a freely available for 
download, set of data is described. It is based on literature peer-reviewed reports and contains hERG inhibition information expressed as IC50 value for 263 
molecules described in 642 records. All studies were done with the use of three cell models (XO, CHO, HEK) and other elements describe the electrophysiological 
settings of the in vitro study. The above mentioned set was used for the successful development of the predictive models. 
 
 
 
  
Background: 
QT prolongation with possible fatal TdP arrhythmia is a common cause of drug 
attrition and relabeling or withdrawals from the market [1]. Thus cardiac 
liability testing of the compounds during the development process has gained 
increased regulatory and public attention. The major cause of QT prolongation 
is connected with a direct block of the hERG channel responsible for the 
delayed rectifier potassium current (IKr) in cardiomyocytes by non-
antiarrhythmic drugs. A wide variety of preclinical in vitro studies are 
employed to evaluate the drug-hERG interactions potential. The accepted and 
recommended standard assay is the measurement of the patch clamp current 
obtained by the expression of hERG in heterologous mammalian cells. 
However the Patch Clamp technique is time-consuming, labor-intensive, 
provides relatively low throughput and generates high costs thus is not 
appropriate at the early stage of the drug development process. Therefore 
insilico screening tests become appreciable and are widely used [2]. Numerous 
molecules or concentrations can be processed simultaneously. Although the 
availability and quality of the datasets used at the models development stage 
are crucial factors. The high sensitivity of the measured channel's inhibition on 
the experimental settings (i.e. cell models, temperature) is a well-known 
phenomenon which cannot be bypassed and has to be considered in the data [3, 
4]. It can be done either at the data preprocessing level with the use of the inter-
settings extrapolation factors or during the modeling stage by introducing 
additional parameters.  
 
Methodology of development: 
As the first step, a preliminary list of drugs known or suspected to have 
cardiotoxic potential has been created, using Fenichel’s database [5], the 
International Registry for Drug Induced Arrhytmias - Arizona resources [6] and 
Roche [7]. Drugs reported to block the hERG channel or IKr were included, 
whereas compounds influencing the cardiac action potential in any other way 
were excluded from the dataset. In order to collect experimental IC50 values 
for hERG of listed drugs Scopus, Medline and Google Scholar searches were 
performed for each drug. There was no time-limit for the search query. Key 
phrases were: the name of the compound of interest and ‘IC50’, or ‘hERG’, or 
‘Human Ether-A-Go-Go’, or ‘potassium channel’, or ‘potassium current’ or 
‘IKr’ either in the article title, keywords or abstract. If there were no results for a 
combination of a compound name with any keyword, the compound’s class 
name was used in the query. The recovered reports were scrutinized for 
additional references not covered by the electronic search. In addition to half-
maximal inhibitory concentration (IC50 value), papers were revised for 
additional information describing experimental settings. The complete set of 
information was gained only for experiments performed with one of the three 
most popular expression systems: Xenopus oocytes, Human Embryonic Kidney 
cells, Chinese Hamster Ovary cells, and if they employed electrophysiology 
assessments. All information was tracked down to the original source, validated 
over the citing article and described by both of them to allow the users to 
recognize them unequivocally [8]. 
 
Utility: 
The obtained dataset is an up to date collection of hERG IC50 values with 
experimental details culled from available scientific literature sources. It 
contains 263 molecular entries, totaling 642 records concerning different in 
vitro measurements. The dataset provides information about the factors with a 
possible influence on IC50 value such as the model applied in experiments, 
measurement techniques, transfection types, experimental conditions 
(temperature and K
+ concentration in external solution) and voltage protocol BIOINFORMATION  open access 
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(protocol type: step, ramp, step-ramp; holding potential, depolarization 
potential, measurement potential; depolarization pulse time). This allows the 
generation of a consistent, homogenous input dataset in order to obtain high 
quality and efficient mathematical models. The molecules included in the 
dataset cover a wide range of IC50 values (10 orders of magnitude) and a broad 
chemical space encompassing drug-specific physico-chemical properties. 
 
Caveats: 
The main limitations of the dataset result from the assumptions made – there is 
a limited number of cell models included, heterogeneity of the measurement 
methods used is high (lack of a standard procedure).  
 
Availability and future developments: 
The described dataset is freely available for download from the project website 
for commercial and non-commercial use [9]. Its development is part of the 
larger project aiming to deliver software for hERG channel inhibition 
prediction. The models used are based on the described dataset completed with 
the drugs physico-chemical parameters. The algorithms utilized cover artificial 
neural networks and RandomForests [10]. Future development plans include a 
regular dataset upgrade based on the newly published peer-reviewed articles. 
Also being considered is the expansion of the dataset by adding new cell 
models (i.e. guinea pig ventricular myocytes). As other ionic currents are 
nowadays recognized as important (i.e. IKs, INa) it is planned to expand the 
project from a single dataset to a database by adding new sets of information. 
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